Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2004

01-09-2004 | Oral presentation

A proinflammatory chemokine, CCL3, sensitizes the heat-gated and capsaicin-gated ion channel, TRPV1

Authors: N Zhang, S Inan, A Cowan, AD Guler, R Sun, J Wang, TJ Rogers, M Caterina, JJ Oppenheim

Published in: Arthritis Research & Therapy | Special Issue 3/2004

Login to get access

Excerpt

Pain, a critical component of host defense, is one of the hallmarks of the inflammatory response. We therefore hypothesized that pain might be exacerbated by proinflammatory chemokines. To test this hypothesis, CCR1 was co-transfected into HEK293 cells together with the Vanilloid Receptor 1 (TRPV1), a cation channel required for certain types of thermal hyperalgesia. Capsaicin induced calcium influx by TRPV1. When CCR1:TRPV1/HEK293 cells were pretreated with CCL3, the sensitivity of TRPV1-mediated calcium flux was increased about fivefold. Pertusis toxin inhibited CCL3-elicited sensitization of TRPV1, indicating the involvement of G-protein signaling. RT-PCR analysis data showed that a spectrum of chemokine and cytokine receptors are expressed in rat dorsal root ganglia (DRG). Immunohistochemical staining of the DRG showed that CCR1 coexpressed with TRPV1 on over 85% of small diameter neurons. CCR1 on neuronal cells was functional, as demonstrated by CCL3-induced calcium flux and protein kinase C activation. Pretreatment with CCL3 enhanced the response of DRG neurons to capsaicin, and this sensitization was inhibited by pertussis toxin, U73122, or staurosporine. Futhermore, injection of CCL3 into mice spine cords enhances the sensitivity of the mice tails toward the hot water, indicative of chemokine-induced sensitization effects in vivo. The fact that a proinflammatory chemokine, by interacting with its receptor on small-diameter neurons, sensitizes TRPV1 reveals a novel mechanism of receptor cross-sensitization that may contribute to hyperalgesia during inflammation. …
Metadata
Title
A proinflammatory chemokine, CCL3, sensitizes the heat-gated and capsaicin-gated ion channel, TRPV1
Authors
N Zhang
S Inan
A Cowan
AD Guler
R Sun
J Wang
TJ Rogers
M Caterina
JJ Oppenheim
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1350

Other articles of this Special Issue 3/2004

Arthritis Research & Therapy 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine